Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Bruno Andraus Filardi"'
Autor:
Vivian do Prado Martins, Karina Dal Sasso Mendes, Bruna Nogueira dos Santos, Bruno Andraus Filardi, Letícia Genova Vieira, Renata Cristina de Campos Pereira Silveira
Publikováno v:
Acta Paulista de Enfermagem, Vol 36 (2023)
Resumo Objetivo Mapear os cuidados em saúde do dispositivo Pegfilgrastim on-body injector na prevenção de neutropenia em adultos com câncer em assistência domiciliar após quimioterapia ambulatorial. Métodos Revisão de escopo baseada na metodo
Externí odkaz:
https://doaj.org/article/c466b7ba2a684f8286abcc76bf86c29e
Autor:
Gislaine Fernandes da Silva, Bruno Andraus Filardi, Hakaru Tadokoro, Carmelia Maria Noia Barreto, Gilberto Lopes, Ramon Andrade de Mello, Mayndra Mychelle Landgraf, Pedro Nazareth Aguiar, Pedro Oliveira
Publikováno v:
Future Oncology. 12:2755-2764
Aim: Concomitant chemoradiotherapy (with cisplatin or carboplatin) is an option of definitive treatment for squamous head and neck cancer. We aimed to perform a meta-analysis comparing those two platinum agents. Materials & methods: We carried out a
Autor:
Pedro Nazareth Aguiar, Pedro Oliveira, Giannis Mountzios, Bruno Andraus Filardi, Gilberto Lopes, Pedro Castelo-Branco, Hakaru Tadokoro, Ramon Andrade de Mello, Ilka Lopes Santoro
Publikováno v:
Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
Background: Recent studies with nivolumab (a monoclonal antibody against programmed cell death 1 [PD-1] receptor) have shown promise non-small-cell lung cancer (NSCLC) treatment. Methods: To review available clinical trials data in order to assess ni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fa853ab15b2992df706f47651769c3d
https://hdl.handle.net/10400.1/9333
https://hdl.handle.net/10400.1/9333
Autor:
Pedro Oliveira, Bruno Andraus Filardi, Gilberto Lopes, Pedro Nazareth Aguiar, Hakaru Tadokoro, Giannis Mountzios, Ilka Lopes Santoro, Ramon Andrade de Mello
Publikováno v:
Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
Background: Tumor programmed death ligand one (PD-L1) expression has been studied in several trials in non-small-cell lung cancer. Methods: We assessed the potential role of PD-L1 expression according to Cochrane Collaboration's Guidelines. Results:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::972b67d2ff847f999c9119b4ca507fd2
https://hdl.handle.net/10400.1/9557
https://hdl.handle.net/10400.1/9557
Autor:
R.A. De Mello, Bruno Andraus Filardi, R. Riera, C.M. Noia Barreto, G. Mountzios, Pedro Nazareth Aguiar, F.S. Picon, Hakaru Tadokoro, P.C. Muniz, A.M. Borges, Pedro Oliveira, Gilberto Lopes, Ilka Lopes Santoro
Publikováno v:
European Journal of Cancer. 51:S566-S567
Autor:
Pedro Oliveira, Ilka Lopes Santoro, P.C. Muniz, Hakaru Tadokoro, Bruno Andraus Filardi, A.M. Borges, Pedro Nazareth Aguiar, F.S. Picon, R.A. De Mello, Gilberto Lopes, G. Mountzios, R. Riera, C.M. Noia Barreto
Publikováno v:
European Journal of Cancer. 51:S644
Autor:
Bruno Andraus Filardi, Ilka Lopes Santoro, P.C. Muniz, R.A. De Mello, G. Mountzios, Hakaru Tadokoro, A.M. Borges, Pedro Oliveira, Gilberto Lopes, R. Riera, C.M. Noia Barreto, Pedro Nazareth Aguiar, F.S. Picon
Publikováno v:
European Journal of Cancer. 51:S624
the combination of amrubicin and topoisomerase II inhibitor irinotecan has yet to be examined in randomized clinical trials. We conducted a randomize phase II study to evaluate the efficacy and safety of amrubicin plus irinotecan (AI) compared with c